The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
GLOW trial: 5-year follow-up of first-line fixed-duration ibrutinib plus venetoclax in older adults with CLL/SLL
|
The phase III GLOW trial (NCT03462719) assessed the safety and efficacy of first-line fixed-duration Ibr + Ven vs Clb + Obi in older adults with CLL/SLL.1 The Lymphoma Hub previously reported the 4-year follow-up outcomes from the GLOW trial. The 5-year follow-up results of this trial were presented at the SOHO 2024 Annual Meeting by Munir.1 |
| Key learnings |
| The estimated 54-month PFS rate was higher in the Ibr + Ven arm vs Clb + Obi arm (67% vs 20%; HR, 0.256). |
| OS was higher and sustained at 57 months in the Ibr + Ven arm vs Clb + Obi arm (HR, 0.453; p = 0.0038). |
| The need for second-line therapy was lower by 82% in the Ibr + Ven arm (HR, 0.185; 95% CI, 0.096–0.355; p < 0.0001). |
| Long-term data from the GLOW trial demonstrate the durable efficacy and tolerable safety profile of Ibr + Ven, supporting its use in older adults with CLL/SLL. |
Abbreviations: CI, confidence interval; Clb, chlorambucil; CLL, chronic lymphocytic leukemia; Ibr, ibrutinib; Obi, obinutuzumab; OS, overall survival; PFS, progression-free survival; SLL, small lymphocytic lymphoma; SOHO, Society of Hematologic Oncology; Ven, venetoclax.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
